Generic Name and Formulations:
Peginterferon beta-1a 125mcg; per prefilled pen or syringe; soln for SC inj; preservative-free.
Indications for PLEGRIDY:
Relapsing forms of multiple sclerosis (MS).
Give by SC inj in abdomen, back of the upper arm, or thigh; rotate inj sites. Initially 63mcg on Day 1, increase to 94mcg on Day 15, then 125mcg on Day 29 and every 14 days thereafter. May give analgesics and/or antipyretics for flu-like symptoms.
Monitor for signs/symptoms of hepatic injury. Depression. Suicidal ideation. Consider discontinuing if depression or other severe psychiatric symptoms occur. Seizure disorder. Discontinue if serious allergic reactions occur. Significant cardiac disease; monitor for worsening condition at initiation and during treatment. Risk of thrombotic microangiopathy; discontinue if occurs. Monitor for infections, bleeding, anemia. Myelosuppression. Monitor CBCs with differential and platelets during treatment. Consider discontinuing if new autoimmune disorder develops. Severe renal impairment; monitor. Pregnancy (Cat.C). Nursing mothers.
Inj site reactions (erythema, pain, pruritus), influenza-like illness, pyrexia, headache, myalgia, chills, asthenia, arthralgia; hepatic injury, seizures, anaphylaxis, CHF, hematologic or autoimmune disorders, inj site necrosis (suspend therapy if multiple lesions occur).
To enroll women exposed to Plegridy during pregnancy call (866) 810-1462 or visit https://www.plegridypregnancyregistry.com/.
Single-dose prefilled pen (0.5mL)—2; Single-dose prefilled syringe (0.5mL)—2; Starter Pack (pens and syringes)—2 (63mcg + 94mcg)
Endocrinology Advisor Articles
- Subclinical Hypothyroidism: Controversies in Testing and Treatment
- Favorable Outcomes With Second-Generation Insulin Analogs in Type 2 Diabetes
- Treatment With Alemtuzumab May Frequently Induce Thyroid Dysfunction
- Type 2 Diabetes and Alzheimer Disease: What's the Connection?
- NT-proBNP May Predict Cardiovascular Outcomes in Type 2 Diabetes
- Using Latent Class Trajectory Analysis to Determine Glucose Response Curve Patterns
- First CGM System With Implantable Glucose Sensor Approved
- Empagliflozin, Linagliptin Combination Therapy vs Linagliptin Monotherapy for Type 2 Diabetes
- Risk for Below Knee Amputations With Canagliflozin vs Other Antihyperglycemic Agents
- Two Phases of C-Peptide Decline Identified in Type I Diabetes
- Effect of SGLT2 Inhibitors on Heart Failure-Related Hospitalization, Below-Knee Amputation
- Nutraceuticals Containing Equol May Be Effective for Postmenopausal Symptoms
- Conservative Monitoring Strategy for Non-Functioning Pituitary Adenomas Evaluated
- FDA: Some Rx Drugs May Become Available Without Seeing a Doctor
- PM2.5 Contributes to Burden of Diabetes Mellitus Globally